A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms PASADENA
- Sponsors Roche
- 08 May 2024 According to a Prothena Corporation media release, data from partner Roche on motor progression in four pre-specified subpopulations from the Phase 2 PASADENA clinical trial published in Nature Medicine.
- 08 May 2024 According to a Prothena Corporation media release, Partner Roche presented important four-year data at AD/PD 2024 from the Phase 2 PASADENA open label extension trial of prasinezumab which impressively continues to show reduced motor and functional progression compared to real-world data from the Michael J. Fox Foundation.
- 18 Apr 2024 Results presented at the 76th Annual Meeting of the American Academy of Neurology 2024